Chemotherapy Induced Anemia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Chemotherapy Induced Anemia - Pipeline Review, H2 2016

Chemotherapy Induced Anemia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Chemotherapy Induced Anemia - Pipeline Review, H2 2016
Published Aug 17, 2016
71 pages — Published Aug 17, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Chemotherapy Induced Anemia - Pipeline Review, H2 2016, provides an overview of the Chemotherapy Induced Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia
- The report reviews pipeline therapeutics for Chemotherapy Induced Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chemotherapy Induced Anemia therapeutics and enlists all their major and minor projects
- The report assesses Chemotherapy Induced Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measure

  
Source:
Document ID
GMDHC8368IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Chemotherapy Induced Anemia Overview81
Therapeutics Development91
  Pipeline Products for Chemotherapy Induced Anemia Overview91
Chemotherapy Induced Anemia Therapeutics under Development by Companies102
Chemotherapy Induced Anemia Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Chemotherapy Induced Anemia Products under Development by Companies151
Chemotherapy Induced Anemia Companies Involved in Therapeutics Development1614
  3SBio Inc.161
  BIOCAD171
  Chong Kun Dang Pharmaceutical Corp.181
  Dr. Reddy's Laboratories Limited191
  Galenica Ltd.201
  Panacea Biotec Limited211
  Pfizer Inc.221
  PharmaEssentia Corporation231
  PhytoHealth Corporation241
  Pieris Pharmaceuticals Inc251
  Sandoz International GmbH261
  SBI Pharmaceuticals Co., Ltd.271
  Therapure Biopharma Inc.281
  Tolero Pharmaceuticals, Inc.291
Chemotherapy Induced Anemia Therapeutics Assessment3010
  Assessment by Monotherapy Products301
  Assessment by Combination Products311
  Assessment by Target322
  Assessment by Mechanism of Action342
  Assessment by Route of Administration362
  Assessment by Molecule Type382
Drug Profiles4023
  (aminolevulinic acid hydrochloride + sodium ferrous citrate) Drug Profile402
  darbepoetin alfa Drug Profile421
  darbepoetin alfa Drug Profile431
  darbepoetin alfa Drug Profile441
  darbepoetin alfa Drug Profile451
  darbepoetin alfa Drug Profile461
  epoetin alfa Drug Profile472
  epoetin zeta Drug Profile493
  ferric carboxymaltose Drug Profile522
  P-1116 Drug Profile541
  PHN-013 Drug Profile551
  PRS-080 Drug Profile562
  SSS-06 Drug Profile581
  TBI-304H Drug Profile591
  TP-0184 Drug Profile601
  TP-0413 Drug Profile611
  TXA-302 Drug Profile621
Chemotherapy Induced Anemia Dormant Projects631
Chemotherapy Induced Anemia Discontinued Products641
Chemotherapy Induced Anemia Product Development Milestones655
  Featured News &Press Releases651
    Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H651
    Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia651
    Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health651
    Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology661
    Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting661
    Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology671
    Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended671
    Aug 09, 2010: Dr Reddy s Launches Darbepoetin Alfa For Treatment Of Anemia In India681
    Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world s first complex biosimilar681
    Jan 07, 2008: Sandoz and Gambro form strategic alliance691
    Aug 31, 2007: European Commission approves Sandoz's epoetin alfa Binocrit691
Appendix702
  Methodology701
  Coverage701
  Secondary Research701
  Primary Research701
  Expert Panel Validation701
  Contact Us701
  Disclaimer711

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Chemotherapy Induced Anemia - Pipeline Review, H2 2016" Aug 17, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Chemotherapy-Induced-Anemia-Pipeline-Review-H2-2016-2088-16394>
  
APA:
Global Markets Direct - Market Research. (2016). Chemotherapy Induced Anemia - Pipeline Review, H2 2016 Aug 17, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Chemotherapy-Induced-Anemia-Pipeline-Review-H2-2016-2088-16394>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.